NZ712797A - Substituted aromatic compounds and related method for the treatment of fibrosis - Google Patents
Substituted aromatic compounds and related method for the treatment of fibrosisInfo
- Publication number
- NZ712797A NZ712797A NZ712797A NZ71279714A NZ712797A NZ 712797 A NZ712797 A NZ 712797A NZ 712797 A NZ712797 A NZ 712797A NZ 71279714 A NZ71279714 A NZ 71279714A NZ 712797 A NZ712797 A NZ 712797A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fibrosis
- alkenyl
- alkyl
- treatment
- aromatic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798269P | 2013-03-15 | 2013-03-15 | |
| PCT/CA2014/000236 WO2014138906A1 (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds and related method for the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ712797A true NZ712797A (en) | 2020-08-28 |
Family
ID=51535669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ712797A NZ712797A (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds and related method for the treatment of fibrosis |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10023518B2 (enExample) |
| EP (1) | EP2970089B1 (enExample) |
| JP (1) | JP6448562B2 (enExample) |
| KR (1) | KR102196721B1 (enExample) |
| CN (2) | CN110105200B (enExample) |
| AR (1) | AR095429A1 (enExample) |
| AU (1) | AU2014231648B2 (enExample) |
| BR (1) | BR112015022008A2 (enExample) |
| CA (1) | CA2905621C (enExample) |
| CL (1) | CL2015002535A1 (enExample) |
| DK (1) | DK2970089T3 (enExample) |
| EA (1) | EA030651B1 (enExample) |
| ES (1) | ES2741439T3 (enExample) |
| IL (1) | IL241178B (enExample) |
| MX (1) | MX379424B (enExample) |
| MY (1) | MY180305A (enExample) |
| NZ (1) | NZ712797A (enExample) |
| PH (1) | PH12015502011B1 (enExample) |
| PL (1) | PL2970089T3 (enExample) |
| PT (1) | PT2970089T (enExample) |
| SG (1) | SG11201507408XA (enExample) |
| TW (1) | TWI689490B (enExample) |
| UY (1) | UY35402A (enExample) |
| WO (1) | WO2014138906A1 (enExample) |
| ZA (1) | ZA201507061B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| US9200004B2 (en) | 2013-01-15 | 2015-12-01 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
| TWI689489B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| EP3203998B1 (en) * | 2014-10-10 | 2021-03-10 | Liminal Biosciences Limited | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
| MY194308A (en) | 2014-10-10 | 2022-11-27 | Prometic Pharma Smt Ltd | Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis |
| JP6720169B2 (ja) * | 2014-11-12 | 2020-07-08 | リミナル・バイオサイエンシーズ・リミテッドＬｉｍｉｎａｌ ＢｉｏＳｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ | 組織の自己修復及び再生のための置換芳香族化合物及び医薬組成物 |
| SG11201707555RA (en) * | 2015-03-18 | 2017-10-30 | Vectus Biosystems Ltd | Compositions for the treatment of kidney and/or liver disease |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US20190144547A1 (en) * | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| US10463645B2 (en) * | 2016-05-19 | 2019-11-05 | Everfront Biotech Inc. | Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis |
| TWI684459B (zh) | 2016-12-15 | 2020-02-11 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療動脈粥樣硬化及其併發症的方法 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| KR102126389B1 (ko) * | 2018-09-14 | 2020-06-25 | 셀라이온바이오메드 주식회사 | 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물 |
| AU2019358595B2 (en) | 2018-10-11 | 2025-04-17 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| IL302014A (en) * | 2020-10-06 | 2023-06-01 | Pharmaceutique Ingenew Inc | Substituted aromatic compounds and pharmaceutical compositions thereof |
| KR102543789B1 (ko) * | 2021-03-08 | 2023-06-20 | 주식회사 온코크로스 | 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183519A1 (en) * | 2001-03-13 | 2002-12-05 | Herbert Nar | Antithrombotic carboxylic acid amides |
| BRPI0711228A2 (pt) * | 2006-05-26 | 2012-06-19 | Auspex Pharmaceuticals Inc | "composto, método de tratar um mamìfero que sofre de um doença ou de uma condição envolvendo as enzimas ciclooxiganase, composição farmacêutica, processo para e deuteração de um composto pelatroca de pelomenos um átomo de hidrogênio do dito composto com um átomo do deutério e processo para preparar m composto" |
| CN101616583A (zh) * | 2007-02-08 | 2009-12-30 | 爱密斯菲尔科技公司 | 苯烷基羧酸输送剂 |
| JP2012526052A (ja) * | 2009-05-04 | 2012-10-25 | プロメティック・バイオサイエンシーズ・インコーポレイテッド | 置換芳香族化合物およびその薬学的使用 |
| DK2427417T3 (da) * | 2009-05-04 | 2014-01-20 | Prometic Biosciences Inc | Salte af 3-pentylphenyleddikesyre og farmaceutiske anvendelser deraf |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
-
2014
- 2014-03-12 TW TW103108723A patent/TWI689490B/zh not_active IP Right Cessation
- 2014-03-13 UY UY0001035402A patent/UY35402A/es not_active Application Discontinuation
- 2014-03-13 AR ARP140100973A patent/AR095429A1/es unknown
- 2014-03-14 CN CN201910355464.7A patent/CN110105200B/zh not_active Expired - Fee Related
- 2014-03-14 SG SG11201507408XA patent/SG11201507408XA/en unknown
- 2014-03-14 ES ES14764458T patent/ES2741439T3/es active Active
- 2014-03-14 PL PL14764458T patent/PL2970089T3/pl unknown
- 2014-03-14 CN CN201480013578.9A patent/CN105189438A/zh active Pending
- 2014-03-14 NZ NZ712797A patent/NZ712797A/en not_active IP Right Cessation
- 2014-03-14 CA CA2905621A patent/CA2905621C/en active Active
- 2014-03-14 MX MX2015011878A patent/MX379424B/es unknown
- 2014-03-14 EP EP14764458.7A patent/EP2970089B1/en active Active
- 2014-03-14 PT PT14764458T patent/PT2970089T/pt unknown
- 2014-03-14 MY MYPI2015002293A patent/MY180305A/en unknown
- 2014-03-14 EA EA201591775A patent/EA030651B1/ru not_active IP Right Cessation
- 2014-03-14 DK DK14764458.7T patent/DK2970089T3/da active
- 2014-03-14 AU AU2014231648A patent/AU2014231648B2/en not_active Ceased
- 2014-03-14 WO PCT/CA2014/000236 patent/WO2014138906A1/en not_active Ceased
- 2014-03-14 BR BR112015022008-8A patent/BR112015022008A2/pt active Search and Examination
- 2014-03-14 US US14/776,328 patent/US10023518B2/en active Active
- 2014-03-14 KR KR1020157029293A patent/KR102196721B1/ko not_active Expired - Fee Related
- 2014-03-14 JP JP2015561849A patent/JP6448562B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-03 IL IL241178A patent/IL241178B/en active IP Right Grant
- 2015-09-09 PH PH12015502011A patent/PH12015502011B1/en unknown
- 2015-09-09 CL CL2015002535A patent/CL2015002535A1/es unknown
- 2015-09-22 ZA ZA2015/07061A patent/ZA201507061B/en unknown
-
2018
- 2018-04-04 US US15/945,408 patent/US10550066B2/en not_active Expired - Fee Related
-
2020
- 2020-02-03 US US16/780,316 patent/US11524930B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502011A1 (en) | Substituted aromatic compounds and related method for the treatment of fibrosis | |
| PH12015502012A1 (en) | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | |
| MX2022003032A (es) | Oxinitruro de piridina, metodo para su preparacion y uso de este. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| IN2014DN09352A (enExample) | ||
| IN2014DN09348A (enExample) | ||
| MX2017000612A (es) | Inhibidores de tirosina quinasa del bazo (syk). | |
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| MD4666B1 (ro) | Inhibitori ai Syk | |
| PH12013502549B1 (en) | Fused benzoxazepinones as ion channel modulators | |
| IL232267A (en) | Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| WO2014099226A3 (en) | Personal cleansing compositions containing zinc amino acid/trimethylglycine halide | |
| MX2014006366A (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| IN2014DN09347A (enExample) | ||
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| WO2012131656A3 (en) | Compounds for use as therapeutic agents affecting p53 expression and/or activity | |
| EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| WO2018071315A3 (en) | Piperidine derivatives as liver x receptor beta agonists, compositions, and their use | |
| EA201591910A1 (ru) | Стабильный раствор бромфенака | |
| MX2015018040A (es) | Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: PROMETIC PHARMA SMT LIMITED, GB Effective date: 20160616 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY ANAQUA SERVICES Effective date: 20210217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2023 BY ANAQUA SERVICES Effective date: 20220218 |
|
| LAPS | Patent lapsed |